Low Testosterone Therapy Lawsuit Claims Increase To Over 2,700 Filings Under MDL

October 26, 2015 (PRLEAP.COM) Health News
Wright & Schulte Represents Men In Low Testosterone Therapy Lawsuit Claims Alleging Testosterone Drug Manufacturers Failed To Warn Of Cardiovascular Risks, Including Heart Attacks, Strokes, And Blood Clots Associated With Prescription Testosterone Treatment Drugs

October 26, 2015 - As pretrial proceedings for testosterone drug therapy lawsuit claims move forward, the number of low testosterone side-effects lawsuit filings continued at a steady rate. Court documents indicate that 2,744 testosterone complaints are pending in the U.S. District Court, Northern District of Illinois, as of October 15. The testosterone treatment complaints allege that men suffer heart attacks, stroke, blood clots, and cardiac death as a result of taking prescription testosterone products such as AndroGel, Axiron and Androderm. (In re: Testosterone Replacement Therapy Product Liability Litigation – MDL No. 2545)

Over 260 complaints were filed in the past month. As of September 15, there were 2,477 lawsuits pending in the multidistrict litigation that consists of six testosterone manufacturers named as defendants. Testosterone gels, patches, creams and injections have been approved by the U.S. Food and Drug Administration (FDA) to treat hypogonadism, which is low testosterone levels in men due to a medical condition and not due to the aging process. (In re: Testosterone Replacement Therapy Product Liability Litigation – MDL No. 2545)

Court records show that in addition to AbbVie and Abbott Laboratories, other testosterone makers named as defendants in the MDL include:

  • Actavis, Inc. and Watson Pharmaceuticals, which makes AndroDerm
  • Auxilium Pharmaceuticals, Inc., which makes Testim
  • Endo Pharmaceuticals Inc., which makes Delatestryl and Fortesta
  • Eli Lilly and Company and Lilly USA LLC, makers of Axiron
  • Pfizer Inc. and its subsidiary, Pharmacia & Upjohn Co. which makes and markets Depo-Testosterone
  • (In re: Testosterone Replacement Therapy ProductLiabilityLitigation –MDL No. 2545)

  • "The fact that testosterone therapy lawsuits filings are increasing indicates that men are experiencing serious cardiac events after taking prescription testosterone products." – Wright & Schulte LLC.

    Wright & Schulte is currently representing men from across the country in testosterone treatment lawsuits and continues to offer legal evaluations to men, or their survivors, who believe they have experienced cardiac events due to testosterone therapy drugs. Contact one of the firms attorneys by calling 1-800-399-0795 or visit www.yourlegalhelp.com for more information on Low-T Drug side-effects and the ongoing testosterone lawsuit litigation.

    Testosterone products have been under investigation by the FDA since January 2014 when the federal regulatory agency announced it was re-evaluating the safety and effectiveness of prescription testosterone medication such as Fortesta and Delatestryl, due to the complaints of cardiovascular risks associated with the products. During its probe, the FDA reviewed studies including one published in JAMA in November 2013 which indicated that testosterone replacement therapy raised the risk of death, heart attack and stroke in men by about 30 percent. The agency also sought input from its advisory committees, which recommended restricting the population of men who are prescribed Low-T products, including men who have problems linked with aging. In March, the FDA directed testosterone makers to place labels on their products warning of the potential increase risk of heart attack or stroke when taking testosterone medication.
    [fda.gov/Safety/MedWatch/SafetyInformation, FDA, January, 31, 2014]
    [fda.gov/Drugs/DrugSafety/ucm436259.htm, FDA, March 3, 2015]

    Court documents indicate that testosterone multidistrict litigation is moving forward with attorneys preparing for bellwether trials. U.S. District Judge Matthew F. Kennelly, who is presiding over the coordinated pretrial proceedings, has ordered the first bellwether trials to involve testosterone lawsuits against AbbVie and Abbot Laboratories, the makers and marketers of AndroGel. Judge Kennelly ordered lawyers for plaintiffs and defendants to each select 16 potential cases for the first six bellwether trials by October 31, 2015. The first AndroGel trial is scheduled to begin in October 2016. (In re: Testosterone Replacement Therapy Product Liability Litigation – MDL No. 2545)

    About Wright & Schulte LLC And Filing A Low Testosterone Therapy Lawsuit: Wright & Schulte LLC, an experienced personal injury firm, is dedicated to the belief that America's legal system should work for the people. Every day, the attorneys of Wright Schulte LLC stand up for the rights of people who have been injured or wronged, and fight tirelessly to ensure that even the world's most powerful corporations take responsibility for their actions. If you're looking for a law firm that will guarantee the aggressive and personal representation you deserve, please do not hesitate to contact Wright & Schulte LLC today. Free testosterone lawsuit case evaluations are available through yourlegalhelp.com, or call 1-888-399-0795.

    Wright & Schulte LLC
    812 East National Road
    Vandalia, Ohio 45377

    Like us on Facebook
    Follow us on Twitter
    Join us on Google+

    Share Article